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ABSTRACT 
Hypothermic machine perfusion (HMP) is regarded a better preservation method for donor 
livers than cold storage. During HMP, livers are perfused through the inlet blood vessels, 
being the hepatic artery (HA) and the portal vein (PV). In previous HMP feasibility studies 
of porcine and human livers, we observed that the PV flow decreased while the HA flow 
increased. This flow competition restored either spontaneously or by lowering the HA 
pressure (PHA). Since this phenomenon was never observed before and affects the HMP 
stability, it is essential to gain more insight into the determinants of flow competition. To 
this end, we investigated during controlled experiments the influence of the HMP boundary 
conditions on liver flows. This paper presents the flow effects induced by increasing PHA 
and by obstructing the outlet blood vessel, being the vena cava inferior (VCI). 
Flow competition was evoked by increasing PHA to 55-70 mmHg, as well as by obstructing 
the VCI. Remarkably, a severe obstruction resulted in a repetitive and alternating tradeoff 
between the HA and PV flow. These phenomena could be related to intra-sinusoidal 
pressure alterations. Consequently, a higher PHA is most likely transmitted to the 
sinusoidal level. This increased sinusoidal pressure reduces the pressure drop between 
the PV and the sinusoids, leading to a decreased PV perfusion. Flow competition has not 
been encountered nor evoked under physiological conditions and should be taken into 
account for the design of liver HMP protocols. Nevertheless, more research is necessary 
to determine the optimal parameters for stable HMP. 
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INTRODUCTION 
Hypothermic machine perfusion (HMP) is an alternative method to preserve organs prior to 
transplantation. Currently, there is a renewed interest in this preservation method given the 
increasing application of so-called “expanded criteria donors” as a countermeasure for the 
growing shortage of organs suitable for transplantation (1, 2). 
In kidney transplantation, HMP optimizes the preservation of kidneys from “expanded 
criteria donors”, assesses their quality prior to transplantation, improves the outcome, and 
eventually increases the number of transplantations (3, 4). In addition, fluid-dynamical and 
biochemical parameters can be monitored during HMP to assess the organ‟s viability. 
Such parameters could help transplant surgeons to discard grafts destined to fail after 
transplantation. HMP has also been suggested to better preserve livers from “expanded 
criteria donors” (5). These livers convey a higher risk of early graft dysfunction and primary 
graft non-function, jeopardizing the outcome for the recipient, especially in the absence of 
liver dialysis and/or an emergency re-transplantation. 
Contrary to the kidney, HMP has not yet become common clinical practice in liver 
transplantation. Several factors such as the complex anatomical and functional features of 
the liver - compared to the kidney - certainly contribute to this. At present, ideal HMP 
settings for livers are still to be defined. These optimal settings should consist of an 
optimal combination of parameters such as the route of perfusion {hepatic artery (HA), 
portal vein (PV), or both}, the concomitant fluid dynamics (continuous or pulsatile perfusion 
and the optimal pressure/flow rates), the perfusion solution, the applied temperature, and 
whether or not to administer oxygen (6). 
Previously, we studied hepatic flow characteristics during HMP feasibility studies on 
porcine livers (7-9) and human livers discarded for clinical transplantation. The default 
temperature and perfusion solution settings were initially similar to those commonly 
applied for renal HMP. Both the HA and PV were continuously perfused with a higher 
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perfusion pressure (P) at the HA compared to the PV. In line with the Lifeport™ technology 
- currently applied for clinical renal HMP and for the liver HMP prototype used in our 
centre - the perfusion flow (Q) through the organ is secondary to the pressure, which is set 
by the operator. As such, in this case, HMP is pressure-driven. 
 
During our initial experience with liver HMP using Lifeport™ technology, vascular 
resistance (VR) was found consistently higher in the HA compared to the PV. During 
perfusion, VRHA gradually decreased (similar to observations in the kidney), resulting in an 
increasing Q since P was kept constant (design and operator controlled). This decrease of 
VR during HMP is thought to reflect the relaxation of the peri-vascular smooth muscle cells 
present in the vessels of the HA vascular bed which are much less developed in the PV. 
To limit the potential shear stresses exerted on the endothelium by a high flow of a cold (4-
6°C) viscous perfusion fluid in the PV (QPV), a flow limitation feature was added to the 
operating facilities of the HMP liver device. 
During some HMP feasibility machine perfusion experiments, a progressive decrease 
and/or a complete cessation of the QPV was observed whilst QHA was increasing as a 
result of the decreasing VRHA. QPV restored either spontaneously or by lowering PHA. This 
phenomenon was defined as flow competition evoked by an increasing QHA and observed 
during HMP of porcine livers as well as a human liver discarded for clinical transplantation, 
which illustrates that the observation was not species-specific. This increasing QHA was 
associated with a progressive decrease of QPV. Hereby, the inflow PHA was remarkably 
higher compared to the PPV. The flow competition was completely reversible when PHA 
was reduced. 
 
The aim of this study was to evaluate whether this phenomenon of flow competition could 
be reproduced in an animal model. Hereby, two hypotheses concerning the induction of 
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flow competition between the HA and PV during liver HMP were tested. Since an elevated 
pressure in the sinusoids reduces the pressure difference between the PV and the 
sinusoids, and consequently reduces QPV, we hypothesized that QPV is hampered as a 
consequence of an elevated sinusoidal pressure. To test this hypothesis, we evaluated 
whether an increased pressure at the sinusoidal level could evoke the previously observed 
flow competition during HMP. First, an increased intra-sinusoidal pressure was evoked by 
an increased PHA (livers 1 – 5). Secondly, as a proof of concept that an increased 
sinusoidal pressure might indeed affect the flow behavior, a moderate or severe 
obstructed hepatic outflow at the level of the supra-hepatic vena cava inferior (VCI) was 
applied to evoke flow competition (liver 3 – 5). In addition, the reversibility of the flow 
competition was investigated. In contrast, the opposite flow competition (by increasing PPV) 
was not examined in this study.  Due to the particular compliance (high flow, low 
resistance) of the portal vasculature, a rise in PPV, would not immediately result in a 
substantial increase of the QPV. Furthermore, a substantial increase of PPV to overcome 
the PHA would result in an extremely high QPV way out of the physiological range. 
 
 
MATERIALS AND METHODS 
Animal model and liver procurement: 
This study was approved by the local animal care committee of the University Hospitals 
Leuven (Belgium). All experiments were carried out in accordance with the federal 
guidelines (10). Five porcine livers (average weight 600 g, from 30-35 kg pigs) were 
procured according to the standard methods of liver retrieval which are routinely applied in 
our lab (11). Pigs were fastened during 12 hours prior to surgery with unlimited access to 
water. Under general anaesthesia, livers were freed from their peritoneal attachments, the 
common bile duct was ligated and the PV, the infra-renal aorta and VCI were prepared for 
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cannulation. Livers were washed-out with 5 litres of 4°C Histidine-Tryptophane-
Ketoglutarate solution retrogradely via the aorta into the HA, and antegradely via the PV. 
The supra-diaphragmatic aorta and supra-hepatic VCI were clamped. The insertion of a 
large cannula in the infra-renal VCI allowed the removal of all blood and Histidine-
Tryptophane-Ketoglutarate solution after hepatic wash-out. Afterwards, the liver was 
removed and prepared for HMP. 
 
Hypothermic machine perfusion: 
Livers were prepared for HMP by cannulation of the PV and the HA with an atraumatic 
“straight-in” cannula. The HA was left in continuity with an aortic conduit. Subsequently, a 
large diameter outflow drain was positioned in the infra-hepatic VCI, whilst the supra-
hepatic VCI was clamped. 
All livers were then perfused using the default settings for clinical HMP of kidneys, as 
adapted for livers in our department (11). Livers were perfused with 2 liters of non-
oxygenated 4-6°C KPS-1™. This perfusion solution is routinely used for renal HMP and is 
similar to the solution originally designed by Belzer (12). A specially designed prototype 
device for liver HMP, the Liver Workstation™ (Organ Recovery Systems, Zaventem, 
Belgium), allowed for a pressure-controlled, flow-unlimited continuous perfusion through 
the HA and a pressure-controlled, flow-limited continuous perfusion through the PV (Figure 
1). QPV was limited to 0.5 ml/g/min (resulting in approximately 300 ml/min for an average 
liver weight of 600 g). This flow limitation feature was implemented in our setting because 
it was previously observed that PPV control alone - even at low temperatures - gave rise to 
very high flow rates {e.g. >2 ml/g/min, (7)}. Such high flows could induce an important 
shear stress during HMP, damaging the sinusoidal endothelial cell lining. Similarly, in 
porcine HMP protocols, flows between 0.4-0.6 ml/g/min have been reported (13,14). 
During HMP, livers were placed in a dome-shaped cassette, and partially immersed in 
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KPS-1™ (Figure 1). Moreover, the device regularly (every 10 minutes) foresees – by its 
design – a short period (10 seconds) to wash-out the tubing. During these periods, the 
organ is not perfused and the pressure drops. After this so-called wash-out, the perfusion 
restarts and the pressure builds up again. 
 
Pressure was measured at the inflow of the HA (PHA) and PV (PPV), immediately proximal 
to the vessels using a pressure sensor and transducer integrated in the HMP device 
(Honeywell, Ohio, USA). The accuracy of these pressure measurements was acquired 
before every experiment through a second measurement using an external pressure 
monitor (Siemens, SC 7000, Dräger Medical, USA) which was calibrated before use. 
Moreover, pressure measurements were first zeroed corresponding to the ambient air 
pressure. Pressure at the supra-hepatic VCI (PVCI) was measured using the external 
pressure sensor, connected to the standard external monitor (Siemens, SC 7000, Dräger 
Medical, USA). Flow rates in the HA and PV were measured separately and expressed as 
ml/min. These measurements were obtained by multiplying the rotations per minute of the 
roller pump by the volume delivered per revolution. Previously, it was found that the 
volume delivered per revolution is constant as long as the pump tubing is not used more 
than 48 hours. The flow rate was measured by a tachometer on the pump motor using a 
digital pulse-counting method to record angular position and speed of the pump. The 
tachometers were integral parts of the applied roller pumps (Alitea, Sweden) on the HMP 
machine. The accuracy of the flow measurements was checked by calibration of the flow 
prior to every experiment. This was done by comparing the flows calculated based on the 
rotation speed of the pumps with the flows acquired by physically collecting the volume of 
perfusate pumped per unit of time prior to the measurements. 
Data acquisition was done continuously throughout the experiment, with a sampling 
frequency of 1 Hz. Based on PHA, PPV and the flow rates of the rotor pumps, VR was 
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calculated as P/Q and expressed as mmHg*min/ml for the HA and PV. Post-processing of 
the acquired data was done using the software packages “Excel” (Microsoft, USA) and 
“Sigmaplot” (Systat Software Inc, USA). The data presented in the figures and tables of 
this paper, are the raw and unfiltered data.  
 
Experimental design: 
Following appropriate insertion of the cannulas in the vessels and positioning of the 
porcine livers (n=5) in the organ cassette, HMP was initiated applying the following 
conditions: PPV≤7 mmHg and QPV≤300 ml/min for the PV inlet, and PHA=25 mmHg with 
unlimited QHA for the HA inlet. After the initiation of HMP perfusion, a stable perfusion 
regime was awaited (approximately 1 hr) before starting the experimental measurements 
until the arterial vascular resistance no longer decreased over time. 
 
 
Two experimental settings were designed to increase the sinusoidal pressure and to study 
whether flow competition could be evoked. After HMP initiation, a stable hepatic flow was 
established to illustrate the competition in each of the five porcine livers either (a) by 
increasing PHA or (b) by obstructing the VCI outflow. 
 
a) Incremental increase of HA inflow pressure/flow 
The initial PHA was set at 25 mmHg and incrementally increased (steps of 10 mmHg) once 
a stable Q was achieved following a given change in PHA. The PHA was increased 
incrementally until a significant decrease in QPV was observed, resulting in a flow 
competition (Table 1, Figure 2). 
In case the maximal QHA (being 300 ml/min as determined by the design of the pumps) 
was reached during the incremental increase of PHA, the PPV was gradually decreased. 
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This was done to evoke flow competition when the limits of the perfusion device were 
encountered. Whenever flow competition was observed, the reversibility was consequently 
investigated by a step-wise decrease of the PHA (Figure 2). 
 
b) Increased outflow resistance at the level of the infra-hepatic VCI 
An outflow obstruction was evoked by clamping the outflow cannula inserted into the VCI. 
This outflow obstruction was done in a controlled way whilst monitoring the pressure at the 
VCI. Two different situations were created (3 experiments for each situation). In a first set 
of experiments, the outflow cannula was clamped to obtain a “moderate” obstruction 
aiming to increase the pressure from a normal value of <1 mmHg to 7-9 mmHg. In a 
second experimental setting, a higher resistance at the outflow was created by a subtotal 
clamp on the outflow tube. This “severe” obstruction resulted in a rise of the pressure at 
the VCI of >9 mmHg whilst complete cessation of the hepatic flow was avoided. 
 
RESULTS 
a) Incremental increase of HA inflow pressure/flow 
In 2/5 experiments (Table 1: livers 1 and 3), increasing the PHA from 25 to 55 mmHg and 
from 25 to 70 mmHg resulted in an increase of the QHA (from 91 to 231 ml/min and from 78 
to 281 ml/min, respectively), evoking a gradual flow competition resulting in a QPV 
cessation at the highest PHA. In 2 other experiments (Table 1: livers 4 and 5; Figure 2), a 
QHA of approximately 300 ml/min was reached (PHA of 49 and 51 mmHg, respectively) 
without a significant decrease in QPV. This is the maximal Q that could be generated by the 
applied pump. Subsequently, flow competition with QPV cessation could then be evoked by 
lowering the inflow PPV to 1 mmHg. Of note, only a substantial decrease of PPV resulted in 
a significant decrease of QPV, since a PPV of 7 mmHg is never reached due to the flow 
limitation feature added. 
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Flow competition could be reversed by lowering PHA (livers 1 and 3) or additionally 
increasing PPV (livers 4 and 5). 
During the experiment with liver 2, the evoked flow competition was not fully reversible 
(Table 1) since it occurred intermittently and continuously after a spontaneous restoration. 
As such, the QPV never stopped completely (indicated in Table 1 by a mean value >0 
ml/min). 
 
b) Increased outflow/back pressure at the level of the infra-hepatic VCI 
Subsequent to the flow competition experiments, a stable P/Q condition - similar to the 
start conditions - was awaited and ensured (PPV≤7 mmHg, QPV≤300 ml/min, PHA=25 
mmHg and QHA unlimited). This resulted in a PVCI≤1 mmHg. 
A moderate outflow obstruction first resulted in a gradual decrease of QHA until a constant 
flow was reached whilst QPV remained stable (Figure 3A and 3B, Table 2). After removal of 
the moderate outflow obstruction, QHA restored to the (pre-outflow obstruction) start values. 
During severe outflow obstruction, a distinctive pattern, defined as a repetitive and 
alternating increase/decrease between QHA and QPV was observed (Table 2, Figure 3C 
and D). First, a decreasing QPV was observed, whilst QHA increased, then followed by a 
spontaneous restoration of QPV with a decreasing QHA. This flow competition pattern or 
interaction repeated itself and was eventually observed to be self-limiting. 
 
DISCUSSION  
Under normal physiological conditions, the hepatic blood flow is well-characterized. 
Approximately 1 ml of blood passes through 1 g of liver every minute (approximately 25-
30% of the cardiac output) (15). About 25% of the total hepatic blood flow is delivered by 
the HA, accounting for half of the livers‟ oxygen supply. The remaining total hepatic blood 
flow and oxygen supply is provided by the PV. Nevertheless, some significant 
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physiological decreases in hepatic blood flow (related to sleep, exercise and expiration) or 
increases (related to feeding, inspiration and aging) are well-described in literature 
(15,16,17). 
 
Under in vivo conditions, intrinsic auto-regulation mechanisms guarantee a constant flow 
through the vascular bed by adaptations of the VR, which is normally lower at the PV and 
higher at the HA (pressure gradient of ±5/20 mmHg between the PV/HA and the hepatic 
veins). This auto-regulation takes place primarily in the HA vascular tree. The peri-vascular 
smooth muscle cell tone of the HA is mediated by stretching and adenosine 
concentrations. Under normal conditions, adenosine is washed away by the portal flow. A 
decreased PV flow, resulting in higher levels of adenosine, induces a vasodilatation of the 
HA, which is followed by an immediate increase of arterial blood flow. This is defined as 
the so-called hepatic arterial buffer response (18). An example of arterial flow decline in 
case of portal hyperperfusion is observed in small or partial liver grafts displaying small for 
size syndrome. Indeed, in partial liver transplantation, liver grafts are subjected to a portal 
flow normally destined for a whole liver. Consequently, portal flow is increased while 
arterial flow decreases (19). 
In contrast to the previously described in vivo buffer response (where portal flow directly 
influences arterial flow), the ex vivo response observed in our study showed that arterial 
pressure/flow directly determines the portal flow. To the author‟s knowledge this has never 
been observed. 
 
Neural regulation is suggested to be of little importance for the hepatic blood flow contrary 
to the numerous effects of humoral regulation (e.g. NO, CO), and the effects of some 
drugs such as volatile anaesthetics, β-adrenergic stimulants, calcium antagonists (20). 
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On a morphological level, hepatic blood flow is mainly regulated at three different sites of 
resistance: at the terminal hepatic arterioles (21), at the arterioles of the splanchnic 
circulation (influencing the portal venous flow), and at the sinusoidal level, more 
specifically at the terminal hepatic venules (22). 
 
Under unphysiological conditions such as isolated liver HMP, information on the function of 
these auto-regulation mechanisms and the interaction between the flow in the HA and PV 
vascular beds are scarce. During ex vivo liver HMP conditions, all hepatic nerves are 
transected and the livers are perfused with a hypothermic a-cellular solution at perfusion 
pressures lower than in physiological in vivo conditions. Previously, we characterized the 
vascular resistance under such conditions and observed a gradual but remarkable 
decrease in the arterial VR during the first 4-6 hours of HMP, while the portal VR remained 
constant (9,11).  
 
The observation of flow competition, defined as a hampered or obstructed flow into the PV 
during HMP, was first occasionally observed during feasibility experiments, but could now 
be consistently evoked when a critical flow into the HA was reached. We hypothesized that 
this results from an increased QHA. Under the HMP settings as applied in our laboratory, 
the Liver Workstation™ for HMP is set to provide arterial perfusion at a constant pressure. 
Normally, during perfusion at hypothermia, HA relaxation can be expected, resulting in an 
increased QHA. An increased sinusoidal pressure can be a consequence of this 
vasorelaxation, despite the higher pressure losses along the HA tree due to the higher 
blood flow. Such an increased sinusoidal pressure could reduce the QPV by decreasing the 
pressure drop between the PV and the sinusoids, thereby reducing the driving force for PV 
perfusion. This seems to make sense, as PHA is higher compared to the PPV, and the 
hepatic natural flow regulation mechanisms, as described above, might be impaired or 
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deficient during the reduced metabolic state of hypothermia. In another study, the blood 
circulation through a human liver was mathematically simulated using an electrical model 
(23). The results of this model illustrated the appearance of flow competition when using 
an increased PHA or obstructed VCI as boundary conditions.  These results support our 
hypothesis that when changing the arterial flow, portal flow changes through an altered 
sinusoidal perfusion. 
Similar observations of flow competition - albeit in a different isolated perfusion model 
using cirrhotic rat livers - were made by Zipprich et al. (24). However, most studies 
concerning liver perfusion did not report any occurrence of flow competition between the 
HA and PV. Table 3 shows an overview of several liver perfusion studies and the 
corresponding perfusion conditions (species, HA and PV perfusion settings, temperature, 
perfusion period, pressure or flow control). To the best of the authors‟ knowledge, and in 
contrast to our experience, none of these studies describes the exact flow and pressure 
profiles over time. Comparing the perfusion setups of Table 3 (26-46), it becomes clear 
that the hydrodynamics and settings are very different. For instance, no flow competition 
will be possible when using flow controlled perfusion, since using those settings the flow is 
prescribed and not allowed to compete between the HA and PV. In addition, other 
parameters (such as the species studied, the application of high/low pressure/flow, 
different routes of perfusion (HA and/or PV), relatively short versus longer periods of HMP 
studied, pulsatile or continuous perfusion…) might also influence the occurrence of this 
phenomenon. Each of these parameters might play a role in whether or not triggering the 
initiation of flow competition, and consequently might be the reason why other groups 
possibly did not observe a similar competition phenomenon.  
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To our knowledge, this ex vivo flow competition interaction was never reported before. We 
speculate that this phenomenon results from an altered function of the pre-sinusoidal 
sphincters at the level of the terminal hepatic arterioles. Such an alteration could be multi-
factorial and induced by the denervation, the use of an a-cellular perfusion solution 
(essentially different from plasma, absence of humoral factors), the hypothermic conditions 
leading to a decreased metabolism and enzymatic activity, the lack of oxygen and 
essential nutrients. Denervation can probably be neglected as a possible cause, since 
hepatic denervation has been shown to have no major deleterious effects on hepatic blood 
flow after liver transplantation (20). A factor which is more likely to contribute is the 
negative influence of the cold temperature (and concomitant intracellular energy depletion) 
on the pre-sinusoidal sphincters. This may eliminate the normal pressure drop between 
these terminal hepatic arterioles and the sinusoids. Consequently, the arterial flow will 
reach the sinusoids at a higher pressure. Other possible explanations for our observations 
can be found in an increased flow through the so-called arteriosinus twigs or in an 
increased resistance of the venous inlet sphincters. 
 
Comparison of the flow competition evoked by PHA alterations and VCI obstructions 
reveals a clear difference. PHA increases led to competition in one direction: QHA increased 
while QPV decreased (Figure 2). In contrast, VCI obstructions affected both QHA and QPV in 
an alternating and repetitive way (Figure 3). 
When theoretically interpreting the hepatic circulation as a passive system, the observation 
of flow competition evoked by an increased PHA would analogously lead to flow 
competition evoked by an increased PPV leading to a decreased QHA. However, we did not 
manage to evoke flow competition by increasing PPV. This can be explained by the fact 
that theoretically {as illustrated by the electrical model of the liver blood flow (23)}, flow 
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competition cannot be reached within the physiological ranges of PPV and QPV by 
increasing the PPV.    
 
However, due to the absence of equipment to directly measure sinusoidal pressure and 
flow in an intact organ, our data do not allow analyzing the mechanisms of the observed 
flow competition more profoundly. As such, the roles of the above discussed potential 
factors contributing to flow competition, are of a speculative nature. We emphasize that the 
flow competition phenomenon was also observed during HMP of human livers in our 
laboratory, supporting the clinical relevance of the observations made in the porcine 
model. The authors acknowledge that the model in its current format has some flaws (such 
as the lack of direct measurement of the sinusoidal pressure), but the observations made 
in this study showed that the flow competition could be consistently reproduced, justifying 
the nature of our hypothesis. 
 
 
These observations might have some important implications on the design and flow control 
for clinical ex vivo machine perfusion devices. Within this study, we were not able to 
deduce a clear pressure/flow threshold that consistently triggers the flow competition in all 
porcine livers. This can be explained by the fact that every porcine liver has its individual 
anatomical features, and consequently, its unique physiological behavior. However, given 
the possibility of flow competition during HMP, we propose general guidelines to achieve a 
fixed arterial inflow limitation as follows. To avoid the occurrence of flow competition during 
HMP, the pressure at the HA inflow should be as low as possible, albeit allowing sufficient 
perfusion of the arterial microvasculature. We would, however, not recommend omitting 
perfusion of the arterial vasculature since it supplies the capillary plexus around the bile 
ducts. Preservation of this bile duct capillary plexus is regarded essential to prevent 
16 
ischemic bile duct strictures after liver transplantation. Consequently, to exclude the 
occurrence of flow competition, we would recommend the use of pressure driven perfusion 
at both the HA and PV side in combination with a flow limitation not only at the PV side, 
but also at the HA side. This flow limitation feature could prevent the onset of flow 
competition by restricting the HA flow. 
 
In conclusion, we observed flow competition between the HA and PV flow during liver 
HMP. This resulted in an impaired and/or inhibited PV flow. Flow competition could be 
evoked by increasing the HA pressure or severe clamping of the VCI, suggesting that this 
is related to alterations in pressure differences between PV and HA, the sinusoids, and the 
HV. This phenomenon should be taken into account when designing appropriate dual 
perfusion protocols for HMP control. 
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ABBREVIATIONS 
HA  Hepatic Artery 
HMP  Hypothermic Machine Perfusion 
P  Pressure 
PV  Portal Vein 
Q  Flow 
VCI  Vena Cava Inferior 
VR  Vascular Resistance 
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Figure 1 
Schematic overview of the liver vasculature and the experimental HMP setup. 
Hypothermic Machine Perfusion (HMP) preservation of the livers is achieved through a 
separate perfusion of the arterial (red) and portal (purple) circulation. Two roller pumps 
provide the inflow of perfusion fluid into the HA and PV via the cannulas and tubing. The 
vascular trees of the HA and PV have a similar topology and branch inside the liver in 
several orders of generations until they finally reach the microvasculature as hepatic 
arterioles and portal venules (see right panel). At this level, perfusion fluid supplied by the 
hepatic arterioles and portal venules enters the periphery of hepatic functional units (the 
lobules) and mixes in the hepatic-specific capillaries (the sinusoids). Consequently, the 
mixture is drained radially until it reaches the central vein. Afterwards, the central venules 
cluster until the fluid reaches the hepatic veins at the outflow of the liver [24]. A large drain 
is placed in the infra-hepatic vena cava inferior which drains the outflow of the liver (blue).  
Once the fluid left the liver, it is recirculated. 
Throughout the HMP experiments, pressures and flows are measured at the level of the 
HA and PV cannulas. In normal conditions, the HA is typically characterized by a high 
pressure and low flow, while the PV is characterized by a low pressure and high flow. 
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Figure 2 
Time-dependent measurements of flow competition as evoked by using liver 5. Panel A 
depicts PHA and panel B depicts PPV, while panel C depicts QHA and QPV. PHA was 
incrementally increased every 10 minutes starting from 25 mmHg. This resulted in an 
incremental QHA increase. Meanwhile, a QPV flow limit (±330 ml/min) was set by the 
operators while the maximal PPV was set at 7 mmHg. A PHA of 50 mmHg (arrow at t=37 
min) evoked a series of decreasing but initially self-restoring QPV. These flow oscillations 
occur as the precursors of a flow instability. Eventually, QPV was hampered indicating the 
initiation of the flow competition (arrow at t=75 min), resulting in a complete cessation of 
QPV. To reverse the flow competition PHA was lowered to 45 mmHg (arrow at t=95 min). 
Portal flow was gradually restored by also increasing the PPV (arrow at t=103 min). Further 
decreasing the PHA (arrow at t=135 min), resulted in a decreased QHA, allowing the full 
restoration of QPV. 
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Figure 3 
Time-dependent measurements of flow competition evoked by the incremental increase of 
sinusoidal pressure caused by a moderate or severe outflow obstruction at the VCI (liver 
4). Panel A and B display the HA and PV pressure and flow measurements, respectively. 
When initiating a moderate obstruction (arrow at t=3 min), QHA decreased until the outflow 
obstruction was stopped (arrow at t=17 min). Meanwhile, QPV as well as PHA and PPV 
remained approximately constant. After the initiation of a severe obstruction (arrow at t=68 
min), an alternating increase/decrease between QHA and QPV was evoked, until the outflow 
obstruction was removed (arrow at t=87 min). Panel C and D are close-ups (t=78-90 min) 
of a part of the severe obstruction. The results showed a repetitive pattern of alternating 
increases and decreases between QHA and QPV. After the initiation of severe outflow 
obstruction, a decrease in QPV was observed with a concomitant QHA increase. 
Subsequently, the QPV recovered spontaneously and QHA decreased. This pattern of 
mutual flow competition (illustrated by the arrows in panel D) was repeated until the severe 
obstruction was removed. The fluctuations were also detectable in the PHA and PPV 
measurements. 
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Table 1 
Overview of the induction of flow competition evoked by increasing PHA in each of the 5 porcine 
livers. Concomitant flows and vascular resistances at the HA and PV inlets were measured and 
calculated. PHA was incrementally increased. When flow competition was evoked (indicated by *), 
PHA was gradually decreased, which allowed reversal of the flow competition in all livers (except for 
liver 2). In livers 3, 4 and 5, the maximal QHA of ±300 ml/min (limitation of the HMP pump) was 
reached by increasing the PHA. Subsequently, PPV was incrementally decreased in those livers. 
Data are presented as mean values of P, Q and VR of the HA and PV. 
 
 PHA  
(mmHg) 
QHA 
(ml/min) 
VRHA 
(mmHg 
*min/ml) 
PPV  
(mmHg) 
QPV 
(ml/min) 
VRPV 
(mmHg 
*min/ml) 
Liver 1 25 91 0.27 3 128 0.023 
 35 143 0.24 3 166 0.018 
 45 194 0.23 3 121 0.025 
 55 231 0.24 3 14* 0.21 
 45 197 0.23 3 10 0.3 
 35 169 0.21 3 8 0.37 
 25 149 0.17 4 91 0.044 
Liver 2 25 37 0.68 5 174 0.029 
 35 109 0.32 8 154 0.052 
 45 152 0.29 8 184 0.043 
 54 144 0.38 4 70* 0.057 
Liver 3 25 78 0.32 3 228 0.013 
 40 138 0.29 4 204 0.019 
 59 232 0.25 3 97 0.031 
 70 281 0.25 4 8* 0.5 
31 
 60 266 0.24 1 0 - 
 50 211 0.24 4 135 0.029 
 40 174 0.23 3 166 0.018 
Liver 4 24 142 0.17 0.62 262 0.0038 
 35 192 0.18 0.35 307 0 
 45 249 0.18 0.43 295 0 
 49 287 0.17 1.23 303 0.0033 
 64 289 0.22 0.51 19* 0.053 
 55 262 0.21 0.71 0 - 
 45 244 0.18 0.93 0 - 
 35 183 0.19 2.66 123 0.024 
Liver 5 25 119 0.21 3 240 0.013 
 35 188 0.19 3 242 0.012 
 44 273 0.16 3 203 0.015 
 51 288 0.18 2 168 0.012 
 45 250 0.18 0 4* 0 
 34 211 0.16 3 223 0.014 
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Table 2 
Overview of the induction of flow competition evoked by hepatic outflow obstruction as observed 
during experiments with livers 3, 4 and 5. For moderate outflow obstruction, data are given at the 
moment just before, during and after the obstruction. In this case, QHA decreased whilst QPV 
remained stable despite the increased vascular resistance, indicated by a higher PPV. After the 
obstruction, QHA returned to the initial values (see also Figure 3). In contrast, a repetitive and 
alternating increase/decrease between QHA and QPV was observed during the severe obstruction. 
First, a decreasing QPV was observed, whilst QHA increased, followed by a spontaneous restoration 
of QPV with a decreasing QHA (see Figure 3). Time stamp “1” corresponds with the moment where 
QPV starts decreasing while QHA is increasing, “2” corresponds with the moment when the reverse 
phenomenon is observed. 
 
 Type 
obstruction 
Time 
stamp 
PVCI 
(mmHg) 
PHA  
(mmHg) 
QHA 
(ml/min) 
PPV  
(mmHg) 
QPV 
(ml/min) 
Liver 3 Moderate before obstruction - 25 67 3 297 
  during obstruction 6 25 45 6 296 
  after obstruction - 25 60 4 293 
 Severe 1 10 59 232 3 130 
    59 230 4 135 
    59 230 6 138 
  2 10 58 238 3 0 
    58 242 2 0 
    58 245 2 0 
33 
Liver 4 Moderate before obstruction - 25 103 7 284 
  during obstruction 5 25 86 7 266 
  after obstruction - 25 98 5 288 
 Severe 1 13 27 89 14 240 
    28 83 17 242 
    26 113 7 217 
    25 117 7 207 
  2 13 25 120 5 0 
    25 123 4 0 
    25 136 2 0 
    25 139 2 0 
Liver 5 Moderate before obstruction - 25 119 4 296 
  during obstruction 4 25 99 7 274 
  after obstruction - 24 125 4 303 
 Severe 1 10 26 92 9 228 
    25 94 11 246 
    27 83 14 266 
  2 10 25 120 3 0 
    24 118 3 0 
    24 143 1 0 
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Table 3 
Overview of several liver perfusion studies (13,26-47) and the corresponding perfusion conditions 
(species, HA and PV perfusion settings, temperature, perfusion period, pressure or flow control) 
during experimental and clinical machine perfusion preservation of livers (C = Continuous, P = 
pulsatile). 
Author and year of publication Species PV HA Temp (°C) 
Perfusion 
period 
(hours) 
Perfusion 
control 
Slapak et al., 1969 (26) Canine 0.23-0.59 ml/min/g (2:1 
ratio PV flow over HA flow) 
 
76/23 mmHg (P) 
11 6 Pressure (PV) 
  8.8-10.3 mmHg     
Brettschneider et al., 1968 (27) Canine 4.8 ml/min/g 1.2 ml/min/g 4 8-12 Flow 
Belzer et al., 1970 (28) Porcine 5-8 mmHg 60/40 mmHg (P) 8-10 8-24 Pressure (HA) 
Flow (PV) 
Gellert et al., 1985 (29) Porcine 2 mmHg (C) 80/40 mmHg (P) 10-12 6 Flow  
  0.5 ml/min/g 0.125 ml/min/g    
Pienaar et al., 1990 (30) Canine 16-18 mmHg (P; 30 bpm) - 5 72 Pressure 
Boudjema et al., 1991 (31) Rabbit 15-25 mmHg - 5 24-48 Pressure 
Yamamoto et al., 1991 (32) Porcine 0.5-0.6 ml/min/g - 7 72 Flow 
Rossaro et al., 1992 (33) Rat 0.5 ml/min/g - 6-10 24 Flow 
Kim et al., 1997 (34) Rat 11 mmHg - 4 48 Flow 
  0.5 ml/min/g     
Kozaki et al., 1997 (35) Porcine 7-8 mmHg 50-60 mmHg 8 2 Pressure 
Iwamoto et al., 2000 (36) Porcine 7-8 mmHg 50-60 mmHg 8 2 Pressure 
   20-30 mmHg    
Southard et al., 2000 (37) Rat 0.14 ml/min/g - 4 24 Flow 
Compagnon et al., 2001 (38) Rat 0.4 ml/min/g 0.1 ml/min/g 4 24 Flow 
Uchiyama et al., 2001 (39) Porcine - 30-60 mmHg (P or 
not) 
8 2 Pressure 
Dutkowski et al., 1998 (40) Rat 4.48 ± 0.54 mmHg - 3-6 10     
  0.44 ml/min/g     
Lauschke et al., 2003 (41) Rat 0.5 ml/min/g - 4 0.75 Flow 
Guarrera et al., 2005 (14) Human/ 
Porcine 
3-5 mmHg 
0.7 ml/min/g 
12-18 mmHg 3-5 5-10 
12 
Flow 
Flow 
Jain et al., 2005 (42) Porcine 10-12 mmHg 
0.3 mL/min/g 
30 mmHg 
0.1 ml/min/g  
Hypothermic 24 Pressure 
„t Hart et al., 2007( 43) Rat 4/8 mmHg 25/50 mmHg (P) 1-3 24 Pressure 
  350 ml/min 80 ml/min    
Vekemans et al., 2007 (8) Porcine 3-5/7 mmHg 20/25 mmHg 4-7 24 Pressure 
  0.5-1 ml/min/g     
De Rougemont et al., 2009 (13) Porcine  Unknown - 4-8 1  
Guarrera et al., 2010 (44) Human 2.9 mmHg 5.5 mmHg 4-6 3-7 Flow 
Butler et al., 2002 (45)  Porcine 7.22 mmHg 
1.75 l/min 
90.3 mmHg 
240 ml/min 
39  
(Normothermic) 
72 Pressure (PV) 
Flow (HA) 
Schon et al., 2001 (46) Porcine 11 mmHg 
250 ml/min 
100 mmHg 
150 ml/min 
37 
(Normothermic) 
4 Pressure 
 
